MRI fusion biopsy datasets

32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom

638

Diagnostic performance of multiparametric MRI in prostate cancer: Per core analysis of three prospective ultrasound/MRI fusion biopsy datasets Eur Urol Suppl 2017; 16(3);e1101

Ferriero M.1, Giacobbe A.2, Papalia R.3, Collura D.2, Altobelli E.3, Mastroianni R.3, Tuderti G.1, Minisola F.1, Misuraca L.1, Guaglianone S.1, Muto G.3, Gallucci M.1, Simone G.1 1

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2San Giovanni Bosco Hospital, Dept. of Urology, Turin, Italy, 3Campus Bio-Medico University, Dept. of Urology, Rome, Italy INTRODUCTION & OBJECTIVES: The fusion of multiparametric (Mp) magnetic resonance imaging (MRI) with real time 3D ultrasound during prostate biopsy is gaining popularity. The aim of this study was to evaluate the diagnostic performance of Mp-MRI using a per-core analysis of patients who underwent prostate “fusion” biopsy. MATERIAL & METHODS: Baseline, clinical and pathological data of 498 consecutive patients who underwent Mp-MRI/ultrasound “fusion” biopsy of prostate were prospectively collected in three centres between October 2013 and October 2016. The UroStation™ (Koelis, France) and ultrasound system with an end-fire 3D TRUS transducer were used for the imaging fusion process. Diagnostic accuracy of Mp-MRI was evaluated in the whole cohort and in those patients with Gleason score >6, separately. Sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and accuracy (Ac) of Mp-MRI were assessed on the base of a per core analysis of histologic findings. RESULTS: Out of 498 patients, 286 had a PCa diagnosis (57.4%); 162 of them (32.5%) were Gleason score ≥7. Overall, 9360 cores were taken: Se, Sp, PPV, NPV and Ac of Mp-MRI in the whole cohort were 46.5%, 81.7%, 36.6%, 87% and 75.2%, respectively. When restricting the analysis to Gleason scores >6, Se, Sp, PPV, NPV and Ac were 45.9%, 79.8%, 25.1%, 90.9% and 75.4%, respectively. In a per patient analysis, the detection rate of PI-RADS scores 3,4 and 5 were 24%, 68% and 93.6%, respectively, while for Gleason score PCa>6 the detection rate of PIRADS 3, 4 and 5 were 6%, 35.2% and 73.4%, respectively.(Table 1). In a per core analysis, the PPV of PI-RADS scores 3,4 and 5 were 8.5%, 37.8% and 73.2%, respectively, while the PPV of PI-RADS scores for Gleason score PCa>6 were 5.1%, 21.2% and 62.2%, respectively (Table 2). Demographic data are reported into Table 1.

Eur Urol Suppl 2017; 16(3);e1101

32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom

638

Diagnostic performance of multiparametric MRI in prostate cancer: Per core analysis of three prospective ultrasound/MRI fusion biopsy datasets Eur Urol Suppl 2017; 16(3);e1102

Table 1 Age (mean ± SD) Baseline PSA (mean ± SD) Previous biopsy N (%) Previous negative biopsy (%) Number of MRI suspicious foci (mean ± SD) Number of cores taken (mean ± SD) Number of target cores taken (mean ± SD) PIRADS score (median; IQR)

Table 2 Per patient analysis Detection rate (%) Per core analysis PPV (%)

PIRADS score 3 4 5 3 4 5

66.3 ± 7.98 9.8 ± 7.2 200 (40.1) 162 (32.5) 1.24 ± 0.51 18.8 ± 6.26 4.37 ± 2.77 4; 3-4

Any G score 24 68 93.6 9.5 37.8 73.2

G score≥7 6 35.2 73.4 5.1 21.2 62.2

CONCLUSIONS: This study confirmed high PCa detection rates with Mp-MRI-ultrasound fusion biopsy. A meticulous analysis of 9360 biopsy cores taken showed a poor sensitivity and PPV of Mp-MRI, especially for Gleason score >6 PCa. Despite the poor discrimination of PI-RADS scores of 3 and 4, PIRADS scores 5 correctly identified PCa lesions with Gleason scores >6.

Eur Urol Suppl 2017; 16(3);e1102 Powered by TCPDF (www.tcpdf.org)